COPD: Epidemiology Overview and Insights

  • ID: 4523573
  • Report
  • 50 pages
  • Pharma Scroll
1 of 4

FEATURED COMPANIES

  • Abdi Ibrahim
  • Cipla
  • Endo International
  • Innoviva
  • Merck & Co
  • Pfizer
  • MORE
“COPD: Epidemiology Overview and Insights” report delivers an in-depth understanding of the disease and the historical & forecasted epidemiology of COPD disease in terms of diagnosed prevalent and the treated patients in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan market till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Disease Indication Overview:
This section of the report gives the overview of COPD disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and further details the types of COPD disease. Further details on the profile of COPD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for COPD disease.

Epidemiology Forecasts to 2024:
This section of the report provides the overview of COPD diagnosed prevalent and treated patients in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Why Purchase the Report:
  • Robust Disease Diagnosed prevalent population numbers for companies’ internal use
  • Robust Disease Drug treated population numbers for companies’ internal use
  • Epidemiology numbers forecasted to 2024
  • Epidemiology numbers can be used by companies as inputs to their internal forecast models
  • Multiple Countries coverage
  • Detailed Disease Insights coverage
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abdi Ibrahim
  • Cipla
  • Endo International
  • Innoviva
  • Merck & Co
  • Pfizer
  • MORE
Table of Contents:
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Key Metrics

3 Disease Overview
3.1 Disease Definition
3.2 Disease Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.2.3 Impact on Quality of Life
3.3 Symptoms of the Disease
3.4 Disease Diagnosis
3.5 Treatment Guidelines
3.6 Key unmet needs

4 Disease Epidemiology
4.1 Diagnosed Prevalent Patient projections by Country (Forecast till 2024)
4.1.1 France
4.1.2 Germany
4.1.3 Italy
4.1.4 Spain
4.1.5 United Kingdom
4.1.6 United States
4.1.7 Japan
4.2 Treated Patient projections by Country (Forecast till 2024)
4.2.1 France
4.2.2 Germany
4.2.3 Italy
4.2.4 Spain
4.2.5 United Kingdom
4.2.6 United States
4.2.7 Japan

5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Coverage
5.4 Methodology and Research conducted
5.5 About Us
5.6 Contact Us
5.7 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Boehringer Ingelheim
  • Pfizer
  • Forest Laboratories
  • Mylan
  • AstraZeneca
  • Menarini
  • Allergan
  • Almirall
  • Meda
  • Kyorin Holdings
  • Daewoong Pharmaceutical
  • Circassia
  • Eisai
  • Novartis
  • Sumitomo Dainippon Pharma
  • Meiji Holdings
  • Sosei
  • Vectura
  • SkyePharma
  • GlaxoSmithKline
  • Chiesi
  • Pierre Fabre
  • Laboratorios Farmacéuticos ROVI
  • Handok
  • Grupo Ferrer
  • Mitsubishi Tanabe Pharma
  • Endo International
  • Aspen Pharmacare
  • Faes Farma
  • Dong-A ST
  • Dong-A Socio Holdings
  • Hanmi Pharmaceutical
  • Abdi Ibrahim
  • Merck & Co
  • Astellas Pharma
  • Esteve
  • Elan
  • Innoviva
  • Cipla
  • Takeda
  • Nycomed
  • Theravance Biopharma
  • Pearl Therapeutics
  • PARI Medical Holding
  • Elevation Pharmaceuticals
  • PDL BioPharma
  • Vernalis
  • Verona Pharma
  • Kyowa Hakko Kirin
  • MedImmune
  • Lonza
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll